<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0206222128
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2017
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        FORMIT XR 750 MG TABLETS
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        METFORMIN HYDROCHLORIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        750
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Extended-release tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        45.00
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="SPIMACO" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 488]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SPIMACO ADDWAEIH
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A10BA02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Formit XR Extended release tablets contain the active ingredient metformin hydrochloride and belong to a group of medicines called biguanides, used in the treatment of Type 2 (non-insulin dependent) diabetes mellitus.&nbsp;</p><p>Formit XR is used together with diet and exercise to lower the risk of developing Type 2 diabetes in overweight adults, when diet and exercise alone for 3 to 6 months have not been enough to control blood glucose (sugar). You are at high risk of developing Type 2 diabetes if you have additional conditions like high blood pressure, age above 40 years, an abnormal amount of lipids (fat) in the blood or a history of diabetes during pregnancy.</p><p>The medicine is particularly effective if you are aged below 45 years, are very overweight, have high blood glucose levels after a meal or developed diabetes during pregnancy.</p><p>Formit XR is used for the treatment of Type 2 diabetes when diet and exercise changes alone have not been enough to control blood glucose (sugar).&nbsp;</p><p>Insulin is a hormone that enables body tissues to take glucose from the blood and to use it for energy or for storage for future use. People with Type 2 diabetes do not make enough insulin in their pancreas or their body does not respond properly to the insulin it does make. This causes a buildup of glucose in the blood which can cause a number of serious long-term problems so it is important that you continue to take your medicine, even though you may not have any obvious symptoms. Formit XR makes the body more sensitive to insulin and helps return to normal the way your body uses glucose.</p><p>Formit XR is associated with either a stable body weight or modest weight loss.</p><p>Formit XR Extended release Tablets are specially made to release the drug slowly in your body and therefore are different to many other types of tablet containing metformin.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Formit XR</p><p>Do not take Formit XR if:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You are allergic to metformin or to any of the other ingredients of this medicine (listed in section 6). An allergic reaction may cause a rash, itching or shortness of breath.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have liver problems</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have severely reduced kidney function</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have uncontrolled diabetes, with, for example, severe hyperglycaemia (high blood glucose), nausea, vomiting, diarrhoea, rapid weight loss, lactic acidosis (see &lsquo;risk of lactic acidosis&rsquo; below) or ketoacidosis. Ketoacidosis is a condition in which substances called &lsquo;ketone bodies&rsquo; accumulate in the blood and which can lead to diabetic pre-coma. Symptoms include stomach pain, fast and deep breathing, sleepiness or your breath developing an unusual, fruity smell.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have lost too much water from your body (dehydration). Dehydration may lead to kidney problems, which can put you at risk for lactic acidosis (see &#39;warnings and precautions&rsquo;).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have a severe infection, such as an infection affecting your lung or bronchial system or your kidney. Severe infections may lead to kidney problems, which can put you at risk for lactic acidosis (see &#39;warnings and precautions&rsquo;).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have been treated for acute heart problems or have recently had a heart attack or have severe circulatory problems or breathing difficulties. This may lead to a lack in oxygen supply to tissue which can put you at risk for lactic acidosis (see &#39;warnings and precautions&rsquo;).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You are a heavy drinker of alcohol.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You are under 18 years of age.</p><p><strong>Warnings and precautions </strong></p><p>Risk of lactic acidosis</p><p>Formit XR may cause a very rare, but very serious side effect called lactic acidosis, particularly if your kidneys are not working properly. The risk of developing lactic acidosis is also increased with uncontrolled diabetes, serious infections, prolonged fasting or alcohol intake, dehydration (see further information below), liver problems and any medical conditions in which a part of the body has a reduced supply of oxygen (such as acute severe heart disease).</p><p>If any of the above apply to you, talk to your doctor for further instructions.</p><p>Stop taking Formit XR for a short time if you have a condition that may be associated with dehydration (significant loss of body fluids) such as severe vomiting, diarrhoea, fever, exposure to heat or if you drink less fluid than normal. Talk to your doctor for further instructions.</p><p>Stop taking Formit XR and contact a doctor or the nearest hospital immediately if you experience some of the symptoms of lactic acidosis, as this condition may lead to coma.</p><p>Symptoms of lactic acidosis include:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vomiting</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stomach ache (abdominal pain)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Muscle cramps</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A general feeling of not being well with severe tiredness</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Difficulty in breathing</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reduced body temperature and heartbeat</p><p>Lactic acidosis is a medical emergency and must be treated in a hospital.</p><p>If you need to have major surgery you must stop taking Formit XR during and for some time after the procedure. Your doctor will decide when you must stop and when to restart your treatment with Formit XR.&nbsp;</p><p>During treatment with Formit XR, your doctor will check your kidney function at least once a year or more frequently if you are elderly and/or if you have worsening kidney function.</p><p>If you are older than 75 years, treatment with Formit XR should not be started to lower the risk of developing type 2 diabetes.</p><p>You may see some remains of the tablets in your stools. Do not worry - this is normal for this type of tablet.</p><p>You should continue to follow any dietary advice that your doctor has given you and you should make sure that you eat carbohydrates regularly throughout the day.</p><p>Do not stop taking this medicine without speaking to your doctor.</p><p>Other medicines and Formit XR</p><p>If you need to have an injection of a contrast medium that contains iodine into your bloodstream, in the context of an X-ray or scan, you must stop taking Formit XR before or at the time of injection. Your doctor will decide when you must stop and when to restart your treatment with Formit XR.</p><p>Tell your doctor if you are taking, have recently taken or might take any other medicines. You may need more frequent blood glucose and kidney function tests, or your doctor may need to adjust the dosage of Formit XR. It is especially important to mention the following:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines which increase urine production (diuretics (water tablets) such as furosemide).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines used to treat pain and inflammation (NSAID and COX-2 inhibitors, such as ibuprofen and celecoxib)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Certain medicines for the treatment of high blood pressure (ACE inhibitors and angiotensin II receptor antagonists)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Steroids such as prednisolone, mometasone, beclometasone.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sympathomimetic medicines including epinephrine and dopamine used to treat heart attacks and low blood pressure. Epinephrine is also included in some dental anaesthetics.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines that may change the amount of Formit XR in your blood, especially if you have reduced kidney function (such as verapamil, rifampicin, cimetidine, dolutegravir, ranolazine, trimethoprim, vandetanib, isavuconazole, crizotinib, olaparib).</p><p><strong>Formit XR with alcohol: </strong></p><p>Avoid excessive alcohol intake while taking Formit XR since this may increase the risk of lactic acidosis (see section &lsquo;Warnings and precautions&rsquo;).</p><p>Pregnancy and breast-feeding</p><p>Do not take Formit XR if you are pregnant or breast feeding.</p><p>Ask your doctor or pharmacist for advice before taking any medicine.</p><p>Driving and using machines</p><p>Formit XR taken on its own does not cause &lsquo;hypos&rsquo; (symptoms of low blood sugar or hypoglycaemia, such as faintness, confusion and increased sweating) and therefore should not affect your ability to drive or use machinery. You should be aware, however, that Formit XR taken with other antidiabetic medicines can cause hypos, so in this case you should take extra care when driving or operating machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Your doctor may prescribe Formit XR for you to take on its own, or in combination with other oral antidiabetic medicines or insulin.</p><p>Always take Formit XR exactly as your doctor has told you.</p><p>You should check with your doctor or pharmacist if you are not sure.</p><p>Swallow the tablets whole with a glass of water, do not chew.</p><p>Recommended dose</p><p>Usually you will start treatment with 500 milligrams Formit XR daily. After you have been taking Formit XR for about 2 weeks, your doctor may measure your blood sugar and adjust the dose. The maximum daily dose is 2000 milligrams of Formit XR.</p><p>If you have reduced kidney function, your doctor may prescribe a lower dose.</p><p>Normally, you should take the tablets once a day, with your evening meal.</p><p>In some cases, your doctor may recommend that you take the tablets twice a day. Always take the tablets with food.</p><p>If you take more Formit XR than you should</p><p>If you take extra tablets by mistake you need not worry, but if you have unusual symptoms, contact your doctor. If the overdose is large, lactic acidosis is more likely. Symptoms of lactic acidosis are non-specific, such as vomiting, bellyache with muscle cramps, a general feeling of not being well with severe tiredness, and difficulty in breathing. Further symptoms are reduced body temperature and heart beat.</p><p>If you experience some of these symptoms, you should immediately seek medical attention, as lactic acidosis may lead to coma. Stop taking Formit XR immediately and contact a doctor or the nearest hospital straightaway.</p><p>If you forget to take Formit XR</p><p>Take it as soon as you remember with some food. Do not take a double dose to make up for a forgotten dose.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Formit XR can cause side effects, although not everybody gets them. The following side effects may occur:</p><p>Formit XR may cause a very rare (may affect up to 1 user in 10,000) but very serious side effect called lactic acidosis (see section &lsquo;Warnings and Precautions&rsquo;). If this happens, you must stop taking Formit XR and contact a doctor or the nearest hospital immediately, as lactic acidosis may lead to coma.&nbsp;</p><p>Formit XR may cause abnormal liver function tests and hepatitis (inflammation of the liver) which may result in jaundice (may affect up to 1 user in 10,000). If you develop yellowing of the eyes and/or skin contact your doctor immediately.</p><p>Other possible side effects are listed by frequency as follows:</p><p>Very common (affects more than 1 person in 10):</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diarrhoea, nausea, vomiting, stomach ache or loss of appetite. If you get these, do not stop taking the tablets as these symptoms will normally go away in about 2 weeks. It helps if you take the tablets with or immediately after a meal.</p><p>Common (affects less than 1 person in 10, but more than 1 person in 100):</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Taste disturbance&nbsp;</p><p>Very rare (affects less than 1 person in 10,000):</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decreased vitamin B12 levels</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin rashes including redness, itching and hives.</p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep Formit XR tablets out of the reach and sight of children.</p><p>Do not use them after the expiry date that is printed on the pack.The expiry date refers to the last day of that month.</p><p>Do not store above 30&deg;C</p><p>Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is Metformin Hydrochloride.</p><p>&bull; Formit XR 500 mg: Each extended-release tablet contains 500 mg of Metformin Hydrochloride.</p><p>&bull; Formit XR 750 mg: Each extended-release tablet contains 750 mg of Metformin Hydrochloride.</p><p>&nbsp;</p><p>The other ingredients are: Povidone K 90, Methocel K 100M premium, Colloidal Silicon Dioxide, Magnesium Stearate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Formit XR 500 mg: White to off-white, oval-shaped, biconvex uncoated tablet, engraved
with "76"on one side and plain on the other side.
Formit XR 750mg extended-release tablet is a white, capsule-shaped, biconvex, uncoated
tablet, engraved with “71” on one side and plain on the other side.
FORMIT XR tablets are supplied in cartons containing 30 or 60 tablets per pack.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>SPIMACO</p><p>AlQassim pharmaceutical plant</p><p>Saudi Arabia&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in December 2020.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>أقراص فورميت إكس أر ممتدة المفعول تحتوي على ميتفورمين ھيدروكلورايد<strong> </strong>كمادة فعالة وينتمي إلى مجموعة من الأدوية تسمى بايجوانيد، وتستخدم في علاج مرض السكري النوع الثاني( الغير معتمد على الأنسولين).</p><p>يستخدم فورميت إكس أر جنبا إلى جنب مع النظام الغذائي وممارسة الرياضة ل تقليل خطر الإصابة ب مرض السكري من النوع الثاني في البالغين الذين يعانون من زيادة الوزن . عندما يكون النظام الغذائي وممارسة الرياضة وحدھا لمدة من 3 إلى 6 أشھر غير كافية للسيطرة على جلوكوز الدم (السكر) ،ستكون معرض أكثر للإصابة ب مرض السكري من النوع الثاني إذا كان لديك حالات إضافية&nbsp; مثل ارتفاع ضغط الدم، العمر فوق 40 سنة،&nbsp;&nbsp; كمية غير طبيعية من الدھون في الدم أو كنت قد أصبت من قبل ب مرض السكري أثناء الحمل.&nbsp;</p><p>الدواء فعال بشكل خاص إذا كان عمرك أقل من 45 عاما، تعاني من زيادة الوزن، لديك مستويات عالية من الجلوكوز في الدم بعد تناول الوجبات أو كنت قد أصبت من قبل ب مرض السكري أثناء الحمل.&nbsp;</p><p>يستخدم فورميت إكس أر لعلاج النوع الثاني من مرض السكري عند يكون النظام الغذائي وممارسة التمارين الرياضية وحدھا غير كافية للسيطرة على جلوكوز الدم (السكر)&nbsp; .</p><p>الأنسولين ھو ھرمون يمكّن أنسجة الجسم من تناول جلوكوز الدم واستخدامه للطاقة أو للتخزين لاستعماله في</p><p>المستقبل .الأشخاص المصابون بالسكري من النوع الثاني لا يصنعون ما يكفي الأنسولين في البنكرياس أو أجسامھم لا تستجيب بشكل صحيح للأنسولين الذي تصنعه. ھذا يسبب تراكم&nbsp; الجلوكوز في الدم والذي يمكن أن يسبب عددا من المشاكل الخطيرة على المدى الطويل لذلك من المھم الاستمرار في تناول الدواء ، على الرغم من أنك قد لا يكون لديك أي أعراض واضحة. يجعل فورميت إكس أر الجسم أكثر حساسية للأنسولين ويساعد على عودة الجسم لاستعمال الجلوكوز بشكل الطبيعي&nbsp; .</p><p>تناول فورميت إكس أر يصاحبه إما استقرار الوزن أو خسارة متوسطة في الوزن&nbsp; .</p><p>أقراص&nbsp; فورميت إكس أر ممتدة المفعول صممت خصيصا لجعل الدواء يخرج ببطء في جسمك ، وبالتالي تختلف عن العديد من الأنواع الأخرى من الأقراص التي تحتوي على ميتفورمين&nbsp; .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا تأخذ فورميت إكس أر إذا كنت:&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لديك حساسية من ميتفورمين أو أي من المكونات الأخرى في ھذا الدواء( المدرجة في القسم 6). تفاعل الحساسية قد يسبب طفح جلدي أو حكة أو ضيق في التنفس.&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لديك مشاكل في الكبد&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعاني من ضعف شديد في وظائف الكلى&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لديك سكري لا يمكن السيطرة عليه ، مع ، على سبيل المثال،&nbsp; فرط سكر الدم الشديد( جلوكوز الدم المرتفع) ، والغثيان ، القيء ،الإسھال ، فقدان الوزن السريع ،الحماض اللبني (انظر&quot; خطر الحماض اللبني&quot; أدناه) أو الحماض الكيتوني . الحماض الكيتوني ھو حالة تتراكم&nbsp; فيھا مواد تسمى &quot;كيتونات &quot;في الدم والتي يمكن أن تؤدي إلى أعراض ما قبل غيبوبة السكري. تشمل الأعراض ألم المعدة ، تنفس عميق وسريع، النعاس، رائحة نفس (تنفس) فاكھية غير طبيعية&nbsp; .</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد فقدت الكثير من الماء من جسمك (جفاف) .الجفاف قد يؤدي إلى مشاكل الكلى ، والتي يمكن أن تعرضك لخطر الحماض اللبني (انظر&quot; التحذيرات والاحتياطات&quot;).&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لديك عدوى شديدة ، مثل العدوى التي تؤثر على الرئة أو الشعب الھوائية أو الكلى .العدوى الحادة قد تؤدي إلى مشاكل في الكلى ، والتي يمكن أن تعرضك لخطر الإصابة بالحماض اللبني (انظر &quot;التحذيرات والاحتياطات&nbsp; .)&quot; &bull; قد عولجت من مشاكل قلبية حادة أو كان لديك&nbsp; في الآونة الأخيرة نوبة قلبية أو مشاكل شديدة في الدورة الدموية&nbsp; أو صعوبات في التنفس. ھذا قد يؤدي إلى نقص في إمدادات الأوكسجين إلى الأنسجة التي يمكن أن تضعك في خطر الحماض اللبني (انظر&quot; التحذيرات والاحتياطات&quot;).&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تتناول الكحوليات بكثافة&nbsp; .</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عمرك أقل من 18 عامًا&nbsp; .</p><p><strong>المحاذير والإحتياطات</strong>&nbsp;</p><p><strong>خطر الحماض اللبني&nbsp; </strong></p><p>قد يسبب فورميت إكس أر حالة&nbsp; نادرة جدًا ، ولكنھا خطيرة جدًا&nbsp; تسمى الحماض اللبني ، خاصة إذا كان لديك مشاكل في الكلى. تزيد فرص الإصابة ب الحماض اللبني مع مرض السكري غير المنضبط،&nbsp; العدوى الخطيرة أو الصيام لفترات طويلة أو تناول الكحوليات،&nbsp; الجفاف( انظر مزيد من المعلومات أدناه) ، مشاكل في الكبد وأي حالة طبية يكون فيھا جزء من الجسم يعاني من نقص إمدادات الأكسجين (مثل أمراض القلب الحادة الشديدة&nbsp; .)</p><p>إذا كان أي من الحالات المذكورة أعلاه ينطبق عليك، استشر طبيبك لمزيد من التعليمات.&nbsp;</p><p>توقف عن تناول فورميت إكس أر لفترة قصيرة إذا كان لديك حالة قد تكون مرتبطة بالجفاف (خسارة كبيرة في سوائل الجسم) مثل القيء الشديد،&nbsp; الإسھال والحمى والتعرض للحرارة أو إذا كنت تشرب كمية أقل من السوائل من المعتاد .تحدث إلى طبيبك لمزيد من التعليمات.&nbsp;</p><p>توقف عن تناول فورميت إكس أر واتصل بالطبيب أو أقرب مستشفى على الفور إذا كنت تعاني من بعض أعراض الحماض اللبني ، حيث انه قد تؤدي ھذه الحالة إلى غيبوبة&nbsp; .</p><p>تشمل أعراض الحماض اللبني:&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قيء&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام المعدة (ألم في البطن)&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشنجات العضلات&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور عام بالمرض مع إرھاق شديد&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في التنفس&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض درجة حرارة الجسم ودقات القلب&nbsp;</p><p>الحماض اللبني ھو حالة طبية طارئة ويجب علاجھا في المستشفى&nbsp; .</p><p>إذا كنت بحاجة إلى إجراء عملية جراحية كبرى ، فعليك التوقف عن تناول فورميت إكس أر خلال ولبعض الوقت بعد إجراء العملية .سوف يقرر طبيبك متى يجب عليك التوقف ومتى تستأنف العلاج ب فورميت إكس أر .&nbsp;</p><p>خلال العلاج ب فورميت إكس أر ، سيقوم طبيبك بالتحقق من وظائف الكلى على الأقل مرة واحدة في السنة أو أكثر في كثير من الأحيان إذا كنت من كبار السن و / أو إذا ساءت وظائف الكلى&nbsp; .</p><p>إذا كنت أكبر من 75 عامًا،&nbsp; فلا يجب بدء العلاج ب فورميت إكس أر لتقليل مخاطر الإصابة ب داء السكري من النوع الثاني&nbsp; .</p><p>قد ترى بعض بقايا الأقراص في البراز. لا تقلق ھذا أمر طبيعي لھذا النوع من الأقراص&nbsp; .</p><p>يجب أن تستمر في إتباع أي نصيحة غذائية قدمھا لك الطبيب ويجب عليك التأكد من أنك تتناول الكربوھيدرات بانتظام طوال اليوم&nbsp; .</p><p>لا تتوقف عن تناول ھذا الدواء دون التحدث إلى الطبيب الخاص بك&nbsp; .</p><p><strong>فورميت إكس أر و</strong> <strong>الأدوية أخرى </strong>&nbsp;&nbsp;</p><p>إذا كنت بحاجة إلى حقن سائل تباين يحتوي على اليود في مجرى الدم ، أثناء إجراء أشعة سينية أو مسح ، يجب عليك التوقف عن تناول فورميت إكس أر من قبل أو في وقت الحقن. طبيبك سيقرر متى يجب عليك التوقف وموعد استئناف العلاج ب فورميت إكس أر .&nbsp;</p><p>أخبر طبيبك إذا كنت تتناول، تناولت مؤخرا أو قد تتناول أي أدوية أخرى. قد تحتاج المزيد من اختبارات الجلوكوز في الدم&nbsp; و وظائف الكلى، أو قد يحتاج الطبيب إلى ضبط جرعة فورميت إكس أر. من المھم بشكل خاص الانتباه إلى ما يلي:&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تزيد من إنتاج البول (مدرات البول /أقراص الماء) مثل فوروسيميد&nbsp; .</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المستخدمة لعلاج الألم والالتھاب (مثل مضادات الالتھاب الغير استرويدية ) ومثبطات انزيم كوكس -&nbsp; 2 ، مثل ايبوبروفين و سيلكوكوكسيب .&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية معينة لعلاج ارتفاع ضغط الدم (مثبطات الإنزيم المحول للأنجيوتنسين ومضادات المستقبل الثاني للأنجيوتنسين&nbsp; )</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاسترويدات مثل بريدنيزولون ، موميتاسون ، بيكلوميتازون&nbsp; .</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية محاكيات السيمبثاوي بما في ذلك الايبينفرين و الدوبامين الذي يستخدم لعلاج النوبات القلبية وانخفاض ضغط الدم . يستخدم ايبينفرين أيضا في بعض أدوية التخدير الخاصة ب الأسنان&nbsp; .</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي قد تغير كمية فورميت إكس أر في دمك ، خاصة إذا كانت وظائف الكلى لديك منخفضة (مثل فيراباميل ، ريفامبيسين ، سيميتيدين ، دولوتيجرافير ، رانولازين ، تريميثوبريم ، فانديتانيب ، اسافوكونازول ، كريزوتينيب ، اولاباريب)&nbsp; .</p><p><strong>فورميت إكس أر</strong> <strong>مع الكحول:</strong>&nbsp;</p><p>تجنب الإفراط في تناول الكحول أثناء تناول فورميت إكس أر لأن ھذا قد يزيد من خطر الحماض اللبني (انظر قسم &quot;التحذيرات والاحتياطات&nbsp; .)&quot;</p><p><strong>الحمل والرضاعة الطبيعية</strong>&nbsp;</p><p>لا تتناولي فورميت إكس أر إذا كنت حاملاً أو ترضعين طفلك طبيعيا.&nbsp;</p><p>اسألي طبيبك أو الصيدلي للحصول على المشورة قبل تناول أي دواء&nbsp; .</p><p><strong>القيادة واستخدام الآلات</strong>&nbsp;</p><p>تناول فورميت إكس أر منفردا لا يسبب&quot; hypos&quot; (أعراض انخفاض نسبة السكر في الدم أو نقص جلوكوز الدم ، مثل الضعف</p><p>، الارتباك وزيادة التعرق) ، وبالتالي يجب ألا يؤثر على قدرتك على القيادة أو استخدام الآلات. ومع ذلك ، يجب أن تكون على علم بأن تناول فورميت إكس أر&nbsp; مع أدوية أخرى مضادة لمرض السكر يمكن أن تسبب نقصان نسبة الجلوكوز في الدم ، لذلك في ھذه الحالة يجب أن تأخذ عناية إضافية عند القيادة أو استخدام الآلات&nbsp; .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>قد يصف لك طبيبك فورميت إكس أر منفردا ، أو مع&nbsp; مضادات السكري الفموية الأخرى أو الأنسولين&nbsp; .</p><p>دائما تناول فورميت إكس أر تماما كما أخبرك طبيبك&nbsp; .</p><p>يجب عليك مراجعة طبيبك أو الصيدلي إذا كنت غير متأكد&nbsp; .</p><p>ابتلع الأقراص كاملة مع كوب من الماء ، لا تمضغھا&nbsp; .</p><p><strong>الجرعة الموصى بھا</strong>&nbsp;</p><p>عادة سوف تبدأ العلاج ب 500 ملجم فورميت إكس أر يوميا. بعد تناول فورميت إكس أر لمدة أسبوعين تقريبا ، قد يقيس طبيبك نسبة السكر في الدم و يضبط لك الجرعة.الحد الأقصى للجرعة اليومية ھو 2000 ملجم من فورميت إكس أر .&nbsp;</p><p>إذا كانت وظائف الكلى لديك ضعيفة، قد يصف طبيبك جرعة أقل&nbsp; .</p><p>عادة، يجب أن تتناول الأقراص مرة واحدة في اليوم مع وجبة المساء.&nbsp;</p><p>في بعض الحالات ،قد يوصي طبيبك بأن تتناول الأقراص مرتين في اليوم. تناول دائمًا الأقراص مع الطعام&nbsp; .</p><p><strong>إذا تناولت&nbsp; فورميت إكس أر أكثر مما يجب&nbsp; </strong></p><p>إذا تناولت أقراص زائدة عن طريق الخطأ، فلا داعي للقلق، ولكن إذا كان لديك أعراض غير عادية، فاتصل بطبيبك. إذا كانت الجرعة الزائدة كبيرة ، قد تزيد احتمالية حدوث الحماض اللبني. أعراض الحماض اللبني غير محددة ، مثل القيء ، وألام المعدة &nbsp;مع تقلصات العضلات ، شعور عام بالمرض مع تعب شديد ، صعوبة في التنفس. بالإضافة إلى أعراض أخري مثل انخفاض درجة حرارة الجسم وضربات القلب.&nbsp;</p><p>إذا واجھت بعض من ھذه الأعراض ، يجب عليك على الفور التماس العناية الطبية ، حيث انه قد يؤدي الحماض اللبني إلى غيبوبة. توقف عن تناول فورميت إكس أر على الفور و اتصل بطبيب أو أقرب مستشفى على الفور.&nbsp;</p><p><strong>إذا نسيت أن تتناول أقراص</strong> <strong>فورميت إكس أر</strong>&nbsp;</p><p>يجب عليك أن تتناولھا حالما تتذكر مع بعض الطعام. لا تأخذ جرعة مضاعفة لتعويض الجرعة المنسية&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جميع الأدوية،&nbsp; يمكن أن يسبب فورميت إكس أر أعراض جانبية ، على الرغم من عدم تعرض الجميع لھا. الأعراض الجانبية التالية&nbsp; قد تحدث:&nbsp;</p><p>قد يسبب فورميت إكس أر عرض جانبي نادر جدا (قد يؤثر على 1 من كل 10000 مستخدم) ولكنه خطير جدا يسمى الحماض اللبني (انظر قسم&quot; التحذيرات والاحتياطات&quot;). إذا حدث ھذا ، يجب عليك التوقف عن تناول فورميت إكس أر و الاتصال بالطبيب أو أقرب مستشفى على الفور،&nbsp; حيث انه قد يؤدي الحماض اللبني إلى غيبوبة&nbsp; .</p><p>قد يسبب فورميت إكس أر خلل في اختبارات وظائف الكبد والتھاب الكبد&nbsp; الذي قد ينتج عنه اليرقان (قد يؤثر على 1 من كل 10000 مستخدم ). إذا تعرضت ل اصفرار العينين و / أو الجلد اتصل ب الطبيب على الفور.&nbsp;</p><p>يتم سرد الأعراض الجانبية المحتملة الأخرى حسب نسبة حدوثھا كما يلي:&nbsp;</p><p>شائع جدًا (يصيب أكثر من شخص واحد في كل 10 أشخاص:)&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسھال، الغثيان، التقيؤ، وجع المعدة، فقد الشھية. إذا تعرضت لھذه الأعراض، لا تتوقف عن تناول الأقراص مثل ھذه الأعراض سوف تختفي خلال حوالي أسبوعين .قد يساعدك تناول الأقراص بعد الوجبات.&nbsp;</p><p>شائع( يؤثر على أقل من شخص واحد في كل 10 أشخاص، ولكن أكثر من 1&nbsp; في كل 100 شخص:)&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب التذوق&nbsp; .</p><p>نادرة جدا( تؤثر على أقل من شخص واحد في كل 10000 شخص:)&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستويات فيتامين ) B12بي12)&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي بما في ذلك الاحمرار والحكة والشري&nbsp; .</p><p>إذا تعرضت لأي أعراض جانبية ،تحدث إلى طبيبك أو الصيدلي. يتضمن ذلك أي أعراض جانبية محتملة غير مدرجة في ھذه النشرة&nbsp; .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ الدواء بعيدا عن متناول ونظر الأطفال.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستعمل فورميت إكس أر بعد انتھاء تاريخ الصلاحية المدون على العبوة. وتاريخ الانتھاء يشير إلى أخر يوم في الشھر المذكور.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا يحفظ في درجة حرارة أعلي من 30 درجة مئوية.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب عدم التخلص من الأدوية في مياه المجاري أو قمامة المنزل. اسأل الصيدلي كيف تتخلص من الأدوية التي لم تعد بحاجتھا .لأن ھذه الاعتبارات ستعمل على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المادة الفعالة هى ميتفورمين هيدروكلورايد.</p><p>فورميت إكس أر 500 ملجم: يحتوى كل قرص من فورميت إكس أر ممتد المفعول على 500 ملجم من ميتفورمين هيدروكلورايد. فورميت إكس أر 750 ملجم: يحتوى كل قرص من فورميت إكس أر ممتد المفعول على 750 ملجم من ميتفورمين هيدروكلورايد. المكونات األخرى هى: بوفيدون ك 90 و ميثوسيل ك 100 م ممتاز و سيليكون ثنائى التأكسد غروى و ماغنسيوم ستياريت.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>فورميت إكس أر 500 ملجم: هو قرص أبيض إلى أبيض مائل للصفرة، بيضاوي الشكل، ثنائي التحدب، غير مغلف، محفور بـرقم &quot;76 &quot;على أحد جانبيه وجلي السطح على الجانب األخر. فورميت إكس أر 750 ملجم: هو قرص أبيض، على شكل كبسولة، ثنائي التحدب غير مغلف،محفور برقم &quot;71 &quot;على أحد جانبيه وجلي السطح على الجانب األخر. تتوفر أقراص فورميت إكس أر فى عبوات تحتوى كل عبوة على 30 أو 60 قرص.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>الدوائية</p><p>مصنع األدوية بالقصيم&nbsp;</p><p>المملكة العربية السعودية</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة في ديسمبر 2020.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Formit XR 500 mg extended release tablets.
Formit XR 750 mg extended release tablets.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Formit XR 500 mg: each extended release tablet contains 500 mg metformin hydrochloride.
Formit XR 750 mg: each extended release tablet contains 750 mg metformin hydrochloride.
For excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Extended release tablet.
Formit XR 500 mg extended-release tablet: white to off-white, oval-shaped, biconvex uncoated tablet, engraved with "76"on one side and plain on the other side.
Formit XR 750 mg extended-release tablet: white, capsule-shaped, biconvex, uncoated tablet, engraved with “71” on one side and plain on the other side.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&bull; Reduction in the risk or delay of the onset of type 2 diabetes mellitus in adult, overweight patients with IGT* and/or IFG*, and/or increased HbA1C who are:</p><p>- at high risk for developing overt type 2 diabetes mellitus (see section 5.1) and</p><p>- still progressing towards type 2 diabetes mellitus despite implementation of intensive lifestyle change for 3 to 6 months</p><p>Treatment with Formit XR must be based on a risk score incorporating appropriate measures of glycaemic control and including evidence of high cardiovascular risk (see section 5.1).</p><p>Lifestyle modifications should be continued when metformin is initiated, unless the patient is unable to do so because of medical reasons.</p><p>*IGT: Impaired Glucose Tolerance; IFG: Impaired Fasting Glucose</p><p>&bull; Treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. Formit XR may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p><em>Adults with normal renal function (GFR &ge; 90 mL/min)</em></p><p><em>Reduction in the risk or delay of the onset of type 2 diabetes</em></p><p>&bull; Metformin should only be considered where intensive lifestyle modifications for 3 to 6 months have not resulted in adequate glycaemic control.</p><p>&bull; The therapy should be initiated with one tablet Formit XR 500 mg once daily with the evening meal.</p><p>&bull; After 10 to 15 days dose adjustment on the basis of blood glucose measurements is recommended (OGTT and/or FPG and/or HbA1C values to be within the normal range). A slow increase of dose may improve gastro-intestinal tolerability. The maximum recommended dose is 4 tablets (2000 mg) once daily with the evening meal.</p><p>&bull; It is recommended to regularly monitor (every 3-6 months) the glycaemic status (OGTT and/or FPG and/or HbA1c value) as well as the risk factors to evaluate whether treatment needs to be continued, modified or discontinued.</p><p>&bull; A decision to re-evaluate therapy is also required if the patient subsequently implements improvements to diet and/or exercise, or if changes to the medical condition will allow increased lifestyle interventions to be possible.</p><p><em>Monotherapy in Type 2 diabetes mellitus and combination with other oral antidiabetic agents:</em></p><p>&bull; The usual starting dose is one tablet of Formit XR 500 mg once daily.</p><p>&bull; After 10 to 15 days the dose should be adjusted on the basis of blood glucose measurements. A slow increase of dose may improve gastro-intestinal tolerability. The maximum recommended dose is 4 tablets daily.</p><p>&bull; Dosage increases should be made in increments of 500mg every 10-15 days, up to a maximum of 2000mg once daily with the evening meal. If glycaemic control is not achieved on Formit XR 2000mg once daily, Formit XR 1000mg twice daily should be considered, with both doses being given with food. If glycaemic control is still not achieved, patients may be switched to standard metformin tablets to a maximum dose of 3000 mg daily.</p><p>&bull; In patients already treated with metformin tablets, the starting dose of Formit XR should be equivalent to the daily dose of metformin immediate release tablets. In patients treated with metformin at a dose above 2000 mg daily, switching to Formit XR is not recommended.</p><p>&bull; If transfer from another oral antidiabetic agent is intended: discontinue the other agent and initiate Formit XR at the dose indicated above.</p><p>&bull; Formit XR 750 mg and Formit XR 1000 mg are intended for patients who are already treated with metformin tablets (prolonged or immediate release).</p><p>&bull; The dose of Formit XR 750 mg or Formit XR 1000 mg should be equivalent to the daily dose of metformin tablets (prolonged or immediate release), up to a maximum dose of 1500 mg or 2000 mg respectively, given with the evening meal.</p><p><strong>Combination with insulin</strong></p><p>Metformin and insulin may be used in combination therapy to achieve better blood glucose control. The usual starting dose of Formit XR is one 500 mg tablet once daily, while insulin dosage is adjusted on the basis of blood glucose measurements.</p><p>For patients already treated with metformin and insulin in combination therapy, the dose of Formit XR 750 mg or Formit XR 1000 mg should be equivalent to the daily dose of metformin tablets up to a maximum of 1500 mg or 2000 mg respectively, given with the evening meal, while insulin dosage is adjusted on the basis of blood glucose measurements.</p><p><em>Elderly</em></p><p>Due to the potential for decreased renal function in elderly subjects, the metformin dosage should be adjusted based on renal function. Regular assessment of renal function is necessary (see section 4.4).</p><p>Benefit in the reduction of risk or delay of the onset of type 2 diabetes mellitus has not been established in patients 75 years and older (see section 5.1) and metformin initiation is therefore not recommended in these patients (see section 4.4).</p><p><em>Renal impairment</em></p><p>A GFR should be assessed before initiation of treatment with metformin containing products and at least annually thereafter. In patients at an increased risk of further progression of renal impairment and in the elderly, renal function should be assessed more frequently, e.g. every 3-6 months.</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p>GFR (mL/min)</p></td><td style="vertical-align:top"><p>Total maximum daily dose</p></td><td style="vertical-align:top"><p>Additional considerations</p></td></tr><tr><td style="vertical-align:top"><p>60-89</p></td><td style="vertical-align:top"><p>2000 mg</p></td><td style="vertical-align:top"><p>Dose reduction may be considered in relation to declining renal function.</p></td></tr><tr><td style="vertical-align:top"><p>45-59</p></td><td style="vertical-align:top"><p>2000 mg</p></td><td rowspan="2" style="vertical-align:top"><p>Factors that may increase the risk of lactic acidosis (see section 4.4) should be reviewed before considering initiation of metformin.</p><p>The starting dose is at most half of the maximum dose.</p></td></tr><tr><td style="vertical-align:top"><p>30-44</p></td><td style="vertical-align:top"><p>1000 mg</p></td></tr><tr><td style="vertical-align:top"><p>&lt;30</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Metformin is contraindicated.</p></td></tr></tbody></table><p><em>Paediatric population</em></p><p>In the absence of available data, Formit XR should not be used in children.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                • Hypersensitivity to metformin or to any of the excipients listed in section 6.1.
• Any type of acute metabolic acidosis (such as lactic acidosis, diabetic ketoacidosis)
• Diabetic pre-coma
• Severe renal failure (GFR < 30 mL/min).
• Acute conditions with the potential to alter renal function such as:
- dehydration,
- severe infection,
- shock
• Disease which may cause tissue hypoxia (especially acute disease, or worsening of chronic disease) such as:
- decompensated heart failure,
- respiratory failure,
- recent myocardial infarction,
- shock
• Hepatic insufficiency, acute alcohol intoxication, alcoholism

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Lactic acidosis</u>:</p><p>Lactic acidosis, a very rare, but serious, metabolic complication, most often occurs at acute worsening of renal function or cardiorespiratory illness or sepsis. Metformin accumulation occurs at acute worsening of renal function and increases the risk of lactic acidosis.</p><p>In case of dehydration (severe diarrhoea or vomiting, fever or reduced fluid intake), metformin should be temporarily discontinued and contact with a health care professional is recommended.</p><p>Medicinal products that can acutely impair renal function (such as antihypertensives, diuretics and NSAIDs) should be initiated with caution in metformin-treated patients. Other risk factors for lactic acidosis are excessive alcohol intake, hepatic insufficiency, inadequately controlled diabetes, ketosis, prolonged fasting and any conditions associated with hypoxia, as well as concomitant use of medicinal products that may cause lactic acidosis (see sections 4.3 and 4.5).</p><p>Patients and/or care-givers should be informed of the risk of lactic acidosis. Lactic acidosis is characterised by acidotic dyspnoea, abdominal pain, muscle cramps, asthenia and hypothermia followed by coma. In case of suspected symptoms, the patient should stop taking metformin and seek immediate medical attention. Diagnostic laboratory findings are decreased blood pH (&lt; 7.35), increased plasma lactate levels (&gt;5 mmol/L) and an increased anion gap and lactate/pyruvate ratio.</p><p><u>Renal function</u>:</p><p>GFR should be assessed before treatment initiation and regularly thereafter, see section 4.2. Metformin is contraindicated in patients with GFR&lt;30 mL/min and should be temporarily discontinued in the presence of conditions that alter renal function, see section 4.3.</p><p><u>Cardiac function</u></p><p>Patients with heart failure are more at risk of hypoxia and renal insufficiency. In patients with stable chronic heart failure, metformin may be used with a regular monitoring of cardiac and renal function.</p><p>For patients with acute and unstable heart failure, metformin is contraindicated (see section 4.3).</p><p>Elderly:</p><p>Due to the limited therapeutic efficacy data in the reduction of risk or delay of type 2 diabetes in patients 75 years and older, metformin initiation is not recommended in these patients.</p><p><u>Administration of iodinated contrast agents</u>:</p><p>Intravascular administration of iodinated contrast agents may lead to contrast induced nephropathy, resulting in metformin accumulation and an increased risk of lactic acidosis. Metformin should be discontinued prior to or at the time of the imaging procedure and not restarted until at least 48 hours after, provided that renal function has been re-evaluated and found to be stable, see sections 4.2 and 4.5.</p><p><u>Surgery</u>:</p><p>Metformin must be discontinued at the time of surgery under general, spinal or epidural anaesthesia. Therapy may be restarted no earlier than 48 hours following surgery or resumption of oral nutrition and provided that renal function has been re-evaluated and found to be stable.</p><p><u>Other precautions</u>:</p><p>All patients should continue their diet with a regular distribution of carbohydrate intake during the day. Overweight patients should continue their energy-restricted diet.</p><p>The usual laboratory tests for diabetes monitoring should be performed regularly.</p><p>Metformin alone never causes hypoglycaemia, although caution is advised when it is used in combination with insulin or other oral antidiabetics (e.g. sulphonylureas or meglitinides).</p><p>The tablet shells may be present in the faeces. Patients should be advised that this is normal.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Concomitant use not recommended</u></p><p><em>Alcohol</em></p><p>Alcohol intoxication is associated with an increased risk of lactic acidosis, particularly in case of fasting, malnutrition or hepatic impairment.</p><p><em>Iodinated contrast agents</em></p><p>Metformin must be discontinued prior to or at the time of the imaging procedure and not restarted until at least 48 hours after, provided that renal function has been re-evaluated and found to be stable, see sections 4.2 and 4.4.</p><p><u>Combinations requiring precautions for use</u></p><p>Some medicinal products can adversely affect renal function which may increase the risk of lactic acidosis, e.g. NSAIDs, including selective cyclo-oxygenase (COX) II inhibitors, ACE inhibitors, angiotensin II receptor antagonists and diuretics, especially loop diuretics. When starting or using such products in combination with metformin, close monitoring of renal function is necessary.</p><p><em>Medicinal products with intrinsic hyperglycaemic activity (e.g. glucocorticoids (systemic and local routes) and sympathomimetics).</em></p><p>More frequent blood glucose monitoring may be required, especially at the beginning of treatment. If necessary, adjust the metformin dosage during therapy with the other drug and upon its discontinuation.</p><p><em>Organic cation transporters (OCT)</em></p><p>Metformin is a substrate of both transporters OCT1 and OCT2.</p><p>Co-administration of metformin with</p><p>&bull; Inhibitors of OCT1 (such as verapamil) may reduce efficacy of metformin.</p><p>&bull; Inducers of OCT1 (such as rifampicin) may increase gastrointestinal absorption and efficacy of metformin.</p><p>&bull; Inhibitors of OCT2 (such as cimetidine, dolutegravir, ranolazine, trimethoprim, vandetanib, isavuconazole) may decrease the renal elimination of metformin and thus lead to an increase in metformin plasma concentration.</p><p>&bull; Inhibitors of both OCT1 and OCT2 (such as crizotinib, olaparib) may alter efficacy and renal elimination of metformin.</p><p>Caution is therefore advised, especially in patients with renal impairment, when these drugs are co-administered with metformin, as metformin plasma concentration may increase. If needed, dose adjustment of metformin may be considered as OCT inhibitors/inducers may alter the efficacy of metformin.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>Uncontrolled diabetes during pregnancy (gestational or permanent) is associated with increased risk of congenital abnormalities and perinatal mortality.</p><p>A limited amount of data from the use of metformin in pregnant women does not indicate an increased risk of congenital abnormalities. Animal studies do not indicate harmful effects with respect to pregnancy, embryonic or fetal development, parturition or postnatal development (see section 5.3).</p><p>When the patient plans to become pregnant and during pregnancy, it is recommended that impaired glycaemic control or diabetes are not treated with metformin. For diabetes it is recommended that insulin should be used to maintain blood glucose levels as close to normal as possible to reduce the risk of malformations of the foetus.</p><p><u>Breast-feeding</u></p><p>Metformin is excreted into human breast milk. No adverse effects were observed in breastfed newborns/infants. However, as only limited data are available, breastfeeding is not recommended during metformin treatment. A decision on whether to discontinue breast-feeding should be made, taking into account the benefit of breast-feeding and the potential risk to adverse effect on the child.</p><p><u>Fertility</u></p><p>Fertility of male or female rats was unaffected by metformin when administered at doses as high as 600 mg/kg/day, which is approximately three times the maximum recommended human daily dose based on body surface area comparisons.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Metformin monotherapy does not cause hypoglycaemia and therefore has no effect on the ability to drive or to use machines.</p><p>However, patients should be alerted to the risk of hypoglycaemia when metformin is used in combination with other antidiabetic agents (e.g. sulphonylureas, insulin, or meglinitides).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In post marketing data and in controlled clinical studies, adverse event reporting in patients treated with Formit XR was similar in nature and severity to that reported in patients treated with Formit immediate release.</p><p>During treatment initiation, the most common adverse reactions are nausea, vomiting, diarrhoea, abdominal pain and loss of appetite, which resolve spontaneously in most cases.</p><p>The following adverse reactions may occur with Formit XR.</p><p>Frequencies are defined as follows: very common: &gt;1/10; common &ge;1/100, &lt;1/10; uncommon &ge;1/1,000, &lt;1/100; rare &ge;1/10,000, &lt;1/1,000; very rare &lt;1/10,000.</p><p>Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.</p><p><u>Metabolism and nutrition disorders</u></p><p>Very rare:</p><p>&bull; Lactic acidosis (see 4.4. Special warnings and precautions for use).</p><p>&bull; Decrease of vitamin B12 absorption with decrease of serum levels during long-term use of metformin. Consideration of such an aetiology is recommended if a patient presents with megaloblastic anaemia.</p><p><u>Nervous system disorders</u></p><p><em>Common:</em></p><p>&bull; Taste disturbance</p><p><u>Gastrointestinal disorders</u></p><p><em>Very common:</em></p><p>&bull; Gastrointestinal disorders such as nausea, vomiting, diarrhoea, abdominal pain and loss of appetite. These undesirable effects occur most frequently during initiation of therapy and resolve spontaneously in most cases. A slow increase of the dose may also improve gastrointestinal tolerability.</p><p><u>Hepatobiliary disorders</u></p><p><em>Very rare</em></p><p>&bull; Isolated reports of liver function tests abnormalities or hepatitis resolving upon metformin discontinuation.</p><p><u>Skin and subcutaneous tissue disorders</u></p><p>Very rare:</p><p>&bull; Skin reactions such as erythema, pruritus, urticaria</p><p><u>Reporting of suspected adverse reactions</u></p><p><!--[if gte vml 1]><v:rect id="_x0000_s1026" style='position:absolute;
 left:0;text-align:left;margin-left:-6.55pt;margin-top:19.5pt;width:445.5pt;
 height:126pt;z-index:251660288' filled="f"/><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>To report any side effect(s):</strong></p><p> The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>o Fax: +966-11-205-7662</p><p>o Call NPC at +966-11-2038222, Exts: 2317-2356-2340.</p><p>o Toll free phone: 19999</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: www.sfda.gov.sa/npc</p><p>&nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Hypoglycaemia has not been seen with metformin doses of up to 85 g, although lactic acidosis has occurred in such circumstances. High overdose or concomitant risks of metformin may lead to lactic acidosis. Lactic acidosis is a medical emergency and must be treated in hospital. The most effective method to remove lactate and metformin is haemodialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>ORAL ANTI-DIABETICS</p><p>(A10BA02: Gastrointestinal tract and metabolism)</p><p>Metformin is a biguanide with antihyperglycaemic effects, lowering both basal and postprandial plasma glucose. It does not stimulate insulin secretion and therefore does not produce hypoglycaemia.</p><p><u>Mechanism of action</u></p><p>Metformin may act via 3 mechanisms:</p><p>&bull; reduction of hepatic glucose production by inhibiting gluconeogenesis and glycogenolysis</p><p>&bull; in muscle, by increasing insulin sensitivity, improving peripheral glucose uptake and utilisation</p><p>&bull; and delay of intestinal glucose absorption.</p><p>Metformin stimulates intracellular glycogen synthesis by acting on glycogen synthase.</p><p>Metformin increases the transport capacity of all types of membrane glucose transporters (GLUT).</p><p><u>Pharmacodynamic effects</u></p><p>In clinical studies, the major non glycemic effect of metformin is either weight stability or modest weight loss.</p><p>In humans, independently of its action on glycaemia, immediate release metformin has favourable effects on lipid metabolism. This has been shown at therapeutic doses in controlled, medium-term or long-term clinical studies: immediate release metformin reduces total cholesterol, LDL cholesterol and triglyceride levels. A similar action has not been demonstrated with the extended release formulation, possibly due to the evening administration, and an increase in triglycerides may occur.</p><p><u>Clinical efficacy:</u></p><p><strong><em>Reduction in the risk or delay of type 2 diabetes mellitus</em></strong></p><p>The&nbsp;<strong>Diabetes Prevention Program&nbsp;</strong>(DPP) was a multicenter randomised controlled clinical trial in adults assessing the efficacy of an intensive lifestyle intervention or metformin to prevent or delay the development of type 2 diabetes mellitus. Inclusion criteria were age &ge;25 years, BMI &ge;24 kg/m<sup>2</sup>&nbsp;(&ge;22 kg/m<sup>2</sup>&nbsp;for Asian-Americans), and impaired glucose tolerance plus a fasting plasma glucose of 95 &ndash; 125 mg/dl (or &le;125 mg/dl for American Indians). Patients were either treated with intensive lifestyle intervention, 2x850 mg metformin plus standard lifestyle change, or placebo plus standard lifestyle change.</p><p>The mean baseline values of the DPP participants (n=3,234 for 2.8 years) were age 50.6&plusmn;10.7 years, 106.5&plusmn;8.3 mg/dl fasted plasma glucose, 164.6&plusmn;17.0 mg/dl plasma glucose two hours after an oral glucose load, and 34.0&plusmn;6.7 kg/m<sup>2</sup>&nbsp;BMI. Intensive lifestyle intervention as well as metformin significantly reduced the risk of developing overt diabetes compared to placebo, 58% (95% CI 48-66%) and 31% (95% CI 17-43%), respectively.</p><p>The advantage of the lifestyle intervention over metformin was greater in older persons.</p><p>The patients who benefited most from the metformin treatment were aged below 45 years, with a BMI equal or above 35kg/m<sup>2</sup>, a baseline glucose 2 h value of 9.6-11.0 mmol/l, a baseline HbA<sub>1C</sub>&nbsp;equal or above 6.0% or with a history of gestational diabetes.</p><p>To prevent one case of overt diabetes during the three years in the whole population of the DPP, 6.9 patients had to participate in the intensive lifestyle group and 13.9 in the metformin group. The point of reaching a cumulative incidence of diabetes equal to 50% was delayed by about three years in the metformin group compared to placebo.</p><p>The&nbsp;<strong>Diabetes Prevention Program Outcomes Study&nbsp;</strong>(DPPOS) is the long-term follow-up study of the DPP including more than 87% of the original DPP population for long-term follow up.</p><p>Among the DPPOS participants (n=2776), the cumulative incidence of diabetes at year 15 is 62% in the placebo group, 56% in the metformin group, and 55% in the intensive lifestyle intervention group. Crude rates of diabetes are 7.0, 5.7 and 5.2 cases per 100 person‐years among the placebo, metformin, and intensive lifestyle participants, respectively. Reductions in the diabetes risk were of 18% (hazard ratio (HR) 0.82, 95% CI 0.72&ndash;0.93; p=0.001) for the metformin group and 27% (HR 0.73, 95% CI 0.65&ndash;0.83; p&lt;0.0001) for the intensive lifestyle intervention group, when compared with the placebo group. For an aggregate microvascular endpoint of nephropathy, retinopathy and neuropathy, the outcome was not significantly different between the treatment groups, but among the participants who had not developed diabetes during DPP/DPPOS, the prevalence of the aggregate microvascular outcome was 28% lower compared with those who had developed diabetes (Risk Ratio 0.72, 95% CI 0.63&ndash;0.83; p&lt;0.0001). No prospective comparative data for metformin on macrovascular outcomes in patients with IGT and/or IFG and/or increased HbA<sub>1C </sub>are available.</p><p>Published risk factors for type 2 diabetes include: Asian or black ethnic background, age above 40, dyslipidaemia, hypertension, obesity or being overweight, age, 1st degree family history of diabetes, history of gestational diabetes mellitus, and polycystic ovary syndrome (PCOS).</p><p>Consideration must be given to current national guidance on the definition of prediabetes.</p><p>Patients at high risk should be identified by a validated risk-assessment tool.</p><p><strong><em>Treatment of type 2 diabetes mellitus</em></strong></p><p>The prospective randomised (UKPDS) study has established the long-term benefit of intensive blood glucose control in overweight type 2 diabetic patients treated with immediate release metformin as first-line therapy after diet failure. Analysis of the results for overweight patients treated with metformin after failure of diet alone showed:</p><p>&bull; a significant reduction of the absolute risk of any diabetes-related complication in the metformin group (29.8 events/ 1000 patient-years) versus diet alone (43.3 events/ 1000 patient-years), p=0.0023, and versus the combined sulphonylurea and insulin monotherapy groups (40.1 events/ 1000 patient-years), p=0.0034.</p><p>&bull; a significant reduction of the absolute risk of diabetes-related mortality: metformin 7.5 events/1000 patient-years, diet alone 12.7 events/ 1000 patient-years, p=0.017;</p><p>&bull; a significant reduction of the absolute risk of overall mortality: metformin 13.5 events/ 1000 patient-years versus diet alone 20.6 events/ 1000 patient-years (p=0.011), and versus the combined sulphonylurea and insulin monotherapy groups 18.9 events/ 1000 patient-years (p=0.021);</p><p>&bull; a significant reduction in the absolute risk of myocardial infarction: metformin 11 events/ 1000 patient-years, diet alone 18 events/ 1000 patient-years (p=0.01)</p><p>For metformin used as second-line therapy, in combination with a sulphonylurea, benefit regarding clinical outcome has not been shown.</p><p>In type 1 diabetes, the combination of metformin and insulin has been used in selected patients, but the clinical benefit of this combination has not been formally established.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>After an oral dose of the extended release tablet, metformin absorption is significantly delayed compared to the immediate release tablet with a Tmax at 7 hours (Tmax for the immediate release tablet is 2.5 hours).</p><p>At steady state, similar to the immediate release formulation, Cmax and AUC are not proportionally increased to the administered dose. The AUC after a single oral administration of 2000mg of metformin extended release tablets is similar to that observed after administration of 1000mg of metformin immediate release tablets b.i.d.</p><p>Intrasubject variability of Cmax and AUC of metformin extended release is comparable to that observed with metformin immediate release tablets.</p><p>When the extended release tablet is administered in fasting conditions the AUC is decreased by 30% (both Cmax and Tmax are unaffected).</p><p>Mean metformin absorption from the extended release formulation is almost not altered by meal composition.</p><p>No accumulation is observed after repeated administration of up to 2000mg of metformin as extended release tablets.</p><p>Following a single oral administration of 1500 mg of Formit XR 750 mg, a mean peak plasma concentration of 1193 ng/ml is achieved with a median value of 5 hours and a range of 4 to 12 hours.</p><p>Formit XR 750 mg was shown to be bioequivalent to Formit XR 500 mg at a 1500 mg dose with respect to Cmax and AUC in healthy fed and fasted subjects.</p><p>Following a single oral administration in the fed state of one tablet of Metformin XR 1000 mg, a mean peak plasma concentration of 1214 ng/ml is achieved with a median time of 5 hours (range of 4 to 10 hours).</p><p>When the 1000 mg extended release tablet is administered in fed conditions the AUC is increased by 77% (Cmax is increased by 26% and Tmax is slightly prolonged by about 1 hour).</p><p><strong>Distribution</strong></p><p>Plasma protein binding is negligible. Metformin partitions into erythrocytes. The blood peak is lower than the plasma peak and appears at approximately the same time. The red blood cells most likely represent a secondary compartment of distribution. The mean Vd ranged between 63-276 L.</p><p><strong>Metabolism</strong></p><p>Metformin is excreted unchanged in the urine. No metabolites have been identified in humans.</p><p><strong>Elimination</strong></p><p>Renal clearance of metformin is &gt; 400 ml/min, indicating that metformin is eliminated by glomerular filtration and tubular secretion. Following an oral dose, the apparent terminal elimination half-life is approximately 6.5 hours.</p><p>When renal function is impaired, renal clearance is decreased in proportion to that of creatinine and thus the elimination half-life is prolonged, leading to increased levels of metformin in plasma.</p><p><u>Characteristics in specific groups of patients</u></p><p>Renal impairment</p><p>The available data in subjects with moderate renal insufficiency are scarce and no reliable estimation of the systemic exposure to metformin in this subgroup as compared to subjects with normal renal function could be made. Therefore, the dose adaptation should be made upon clinical efficacy/tolerability considerations (see section 4.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Preclinical data reveal no special hazard for humans based on conventional studies on safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity reproduction.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Povidone K 90, Methocel K 100M premium, Colloidal Silicon Dioxide, Magnesium Stearate</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                For Formit XR 500 mg extended-release tablets: 2 years.
Formit XR 750 mg extended-release tablets: 3 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Transparent thermoformed Reel PVC/PVDC Blister and Aluminum Foil</p><p>Each unit carton contains 30 or 60 tablets</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements. Any unused product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                SPIMACO
AlQassim pharmaceutical plant
Saudi Arabia

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                February 2022.
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>